Investigational drug · Phase 2
Zelenectide pevedotin
Also called: BT8009
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer, Non-Small Cell Lung Cancer, Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
4
Any phase or sponsor naming "Zelenectide pevedotin"
First trial start
2020
Jul 17, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zelenectide pevedotin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Non-Small Cell Lung Cancer
- Advanced Solid Tumors
- Urinary Bladder Neoplasm
- Triple Negative Breast Neoplasms
- Hormone Receptor Positive, HER2-negative Neoplasms
- Hormone Receptor Positive, HER2-low Neoplasms
- Breast Neoplasms
- Non-Small-Cell Lung Neoplasms
- Ovarian Neoplasm
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Zelenectide pevedotin" as an intervention, largest first.
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)Pivotal-lookingActive, not recruiting
BicycleTx LimitedIndustry
NCT06225596 · 375 participants (planned) · Start Jan 24, 2024 · Primary completion Mar 2028
Drug: Zelenectide pevedotin; Zelenectide pevedotin and 3 more · For: Metastatic Urothelial Cancer
Sites: Denver, Colorado; Miami, Florida; Miami Beach, Florida · 102 sites in all
- Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung CancerActive, not recruiting
BicycleTx LimitedIndustry
NCT06933329 · 73 participants (planned) · Start Jul 18, 2025 · Primary completion Aug 31, 2028
Drug: Zelenectide pevedotin · For: Non-Small Cell Lung Cancer
Sites: Paris, France; A Coruña, Spain; Madrid, Spain
- Study of Zelenectide Pevedotin in Participants With Advanced Breast CancerActive, not recruiting
BicycleTx LimitedIndustry
NCT06840483 · 66 participants (planned) · Start Mar 3, 2025 · Primary completion Jun 30, 2028
Drug: Zelenectide pevedotin (BT8009) · For: Breast Cancer
Sites: Baltimore, Maryland; Boston, Massachusetts; St Louis, Missouri · 18 sites in all
- Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational ProductNot yet recruiting
BicycleTx LimitedIndustry
NCT07681674 · 16 participants (planned) · Start Aug 1, 2026 · Primary completion May 30, 2030
Drug: Zelenectide pevedotin; BT7480 and 1 more · For: Advanced Solid Tumors
Newest research
PubMed records naming it or its code names, newest first.
- Characterization of a 64Cu-Labeled Heterobivalent Bicyclic Peptide (Nectin-4/Albumin) for Targeting of Tumor-Associated Nectin-4.
Krönke T, Mauersberger J, Ullrich M, et al. · Mol Pharm 2026
- The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates.
Walsh SJ, Wood F, DeMars LR, et al. · Expert Opin Investig Drugs 2026
- The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.
Lee YHA, Wong CM, Liu AQ, et al. · Curr Opin Urol 2026
- From Cloudy to Clear: A Strategy to Resolve the Complex Structural Elucidation of Bicycle Drug Conjugate Zelenectide Pevedotin by NMR.
Jonasson K, Feilden A, Nesbit W, et al. · Bioconjug Chem 2026
- First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.
Baldini C, Verlingue L, Goldschmidt V, et al. · J Clin Oncol 2025
- Design, synthesis and antitumor evaluation of a novel nectin-4 targeting bicyclic toxin conjugate.
Gu JN, Liu F, Song YS, et al. · Bioorg Med Chem Lett 2025
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.